Eric J Hsu
Overview
Explore the profile of Eric J Hsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
167
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hsu E, Lin T, Dabush D, McCaw Z, Koong A, Lin C, et al.
J Natl Cancer Inst
. 2024 Feb;
116(6):990-994.
PMID: 38331394
Differential censoring, which refers to censoring imbalance between treatment arms, may bias the interpretation of survival outcomes in clinical trials. In 146 phase III oncology trials with statistically significant time-to-event...
2.
Sherry A, Msaouel P, McCaw Z, Abi Jaoude J, Hsu E, Kouzy R, et al.
Eur J Cancer
. 2023 Oct;
194:113357.
PMID: 37827064
Background: The 'Table 1 Fallacy' refers to the unsound use of significance testing for comparing the distributions of baseline variables between randomised groups to draw erroneous conclusions about balance or...
3.
Hsu E, Yan Y, Timmerman R, Wardak Z, Dan T, Patel T, et al.
Radiother Oncol
. 2023 Aug;
188:109874.
PMID: 37640162
Background And Purpose: Radiation oncology protocols for single fraction radiosurgery recommend setting dosing criteria based on assumed risk of radionecrosis, which can be predicted by the 12 Gy normal brain...
4.
Hsu E, Thomas J, Timmerman R, Wardak Z, Dan T, Patel T, et al.
Front Neurol
. 2022 Nov;
13:1024138.
PMID: 36438954
Introduction: Poor outcomes in glioblastoma patients, despite advancing treatment paradigms, indicate a need to determine non-physiologic prognostic indicators of patient outcome. The impact of specific socioeconomic and demographic patient factors...
5.
Hsu E, Thomas J, Maher E, Youssef M, Timmerman R, Wardak Z, et al.
Discov Oncol
. 2022 Nov;
13(1):126.
PMID: 36380219
Purpose: Poor outcomes in IDH wild-type (IDHwt) glioblastomas indicate the need to determine which genetic alterations can indicate poor survival and guidance of patient specific treatment options. We sought to...
6.
Hsu E, Thomas J, Maher E, Youssef M, Timmerman R, Wardak Z, et al.
Front Oncol
. 2022 Sep;
12:1000280.
PMID: 36158642
Introduction: Poor outcomes in glioma patients indicate a need to determine prognostic indicators of survival to better guide patient specific treatment options. While preoperative neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR),...
7.
Hsu E, Mendel J, Ward K, El-Ashmawy M, Lee M, Choy H, et al.
Adv Radiat Oncol
. 2022 Sep;
7(5):100995.
PMID: 36148376
Purpose: Five-fraction stereotactic ablative radiotherapy (SABR) regimens are frequently used to treat centrally located early-stage non-small cell lung cancer or disease in the proximity of the chest wall as a...
8.
Hsu E, Parsons D, Chiu T, Godley A, Sher D, Vo D
3D Print Med
. 2022 Jul;
8(1):22.
PMID: 35844030
Background: Malignancies of the head and neck region, encompassing cutaneous, mucosal, and sarcomatous histologies, are complex entities to manage, comprising of coordination between surgery, radiation therapy, and systemic therapy. Malignancies...
9.
Cao X, Liang Y, Hu Z, Li H, Yang J, Hsu E, et al.
Nat Commun
. 2021 Oct;
12(1):5866.
PMID: 34620867
Type I interferon is promising in treating different kinds of tumors, but has been limited by its toxicity, lack of tumor targeting, and very short half-life. To target tumors, reduce...
10.
Hannan R, Mohamad O, De Leon A, Manna S, Pop L, Zhang Z, et al.
Clin Cancer Res
. 2021 Sep;
27(24):6716-6725.
PMID: 34551906
Purpose: This phase II clinical trial evaluated whether the addition of stereotactic ablative radiotherapy (SAbR), which may promote tumor antigen presentation, improves the overall response rate (ORR) to high-dose IL2...